Jose Ignacio Vargas1, Marco Arrese1,2, Vijay H Shah3, Juan Pablo Arab4,5. 1. Department of Gastroenterology School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. shah.vijay@mayo.edu. 4. Department of Gastroenterology School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. arab.juan@mayo.edu. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. arab.juan@mayo.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. RECENT FINDINGS: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
PURPOSE OF REVIEW: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. RECENT FINDINGS:Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
Authors: J I Germershausen; V M Hunt; R G Bostedor; P J Bailey; J D Karkas; A W Alberts Journal: Biochem Biophys Res Commun Date: 1989-02-15 Impact factor: 3.575
Authors: Juan G Abraldes; Candid Villanueva; Carles Aracil; Juan Turnes; Manuel Hernandez-Guerra; Joan Genesca; Manuel Rodriguez; Jose Castellote; Juan Carlos García-Pagán; Ferran Torres; Jose Luis Calleja; Agustin Albillos; Jaime Bosch Journal: Gastroenterology Date: 2016-01-14 Impact factor: 22.682
Authors: Han Ah Lee; Young Chang; Pil Soo Sung; Eileen L Yoon; Hye Won Lee; Jeong-Ju Yoo; Young-Sun Lee; Jihyun An; Do Seon Song; Young Youn Cho; Seung Up Kim; Yoon Jun Kim Journal: Clin Mol Hepatol Date: 2022-07-01
Authors: David Kockerling; Rooshi Nathwani; Roberta Forlano; Pinelopi Manousou; Benjamin H Mullish; Ameet Dhar Journal: World J Gastroenterol Date: 2019-02-28 Impact factor: 5.742